• 1
    McKenney JM. The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. Pharmacoeconomics 1998;14: 1928.
  • 2
    Datamonitor. Treatment Algorithm: Improving outcomes in hyperlipidaemia? Media Release; Pharmacoeconomics Outcomes News, 1998;188.
  • 3
    Andrade SE, Walker AM & Gottleib LK, et al. Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Eng J Med 1995;332:112531.
  • 4
    Simons LA, Levis G & Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164: 20811.
  • 5
    Lacour A, Derderian F & LeLorier J. Comparison of efficacy and cost among lipid–lowering agents in patients with primary hypercholesterolemia. Can J Cardiol 1998;14:35561.
  • 6
    Avorn J, Monette J & Lacour A, et al. Persistence of use of lipid–lowering medications. JAMA 1998; 279:145862.
  • 7
    Czirak M. Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. PharmacoEconomics 1998;14(Suppl. 3):2938.
  • 8
    Eriksson M, Hadell K, Holme G, Walldius G & Kjellstrom T. Compliance with and efficacy of treatment with prevastatin and cholestryamine: a randomized study on lipid-lowering in primary care. J Int Med 1998;243:37380.
  • 9
    Tamblyn R, Lavoie G, Petrella L & Monette J. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:9991009.DOI: 10.1016/0895-4356(94)00234-h
  • 10
    Von Korff M, Wagner EH & Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197203.
  • 11
    Armitage P & Berry G. Statistical Methods in Medical Research. Oxford: Blackwell Scientific Publications, 1994.
  • 12
    Desgagné A & LeLorier J. Incontinence drug utilization patterns in Québec, Canada. Value Health 2000;2:4528.
  • 13
    Shepherd J, Cohen DJ & Ford I, et al. Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:13017.
  • 14
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:13839.